Shield Therapeutics PLC Additional Listing (7502U)
April 01 2019 - 12:45PM
UK Regulatory
TIDMSTX
RNS Number : 7502U
Shield Therapeutics PLC
01 April 2019
Shield Therapeutics plc
("Shield" or the "Group")
Additional listing
London, UK, 1 April 2019: Shield Therapeutics plc (LSE: STX), a
commercial stage pharmaceutical company with a focus on addressing
iron deficiency with or without anaemia via its lead product
Feraccru(R), announces that it issued and allotted 268,196 Ordinary
Shares of 1.5p each on 21 February 2019 following the exercise of
options under the Shield Therapeutics plc 2016 Company Share Option
Plan.
Application has been made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM. Admission is
expected to be effective on 5 April 2019. The Ordinary Shares shall
rank pari passu with the existing ordinary shares in the
Company.
Following admission, the Company's issued share capital will
comprise 116,694,047 Ordinary Shares and each Ordinary Share
carries one vote. There are no Ordinary Shares held in treasury and
accordingly, the total number of voting rights is 116,694,047. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
- Ends -
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive
Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial Officer
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 7418 8900
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7841 917
Paul McManus / Helen Cresswell 679
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, pharmaceutical company
delivering innovative specialty pharmaceuticals to address
patients' unmet medical needs. The Company's clear purpose is to
help its patients become people again, by enabling them to enjoy
the things that make the difference in their everyday lives. The
Group has a marketed product, Feraccru(R), for the treatment of
iron deficiency in adults which has exclusive IP rights until the
mid-2030s. Feraccru(R) is commercialised in the European Union by
Norgine BV and the US Food and Drug Administration (FDA) is
currently considering a New Drug Application (NDA), with a PDUFA
(Prescription Drug User Fee Act) date of 27(th) July 2019. For more
information please visit www.shieldtherapeutics.com.
(1) -
https://www.shieldtherapeutics.com/rns_news/positive-results-for-feraccru-in-aegis-h2h-study/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ALSDMGGDVMGGLZM
(END) Dow Jones Newswires
April 01, 2019 12:45 ET (16:45 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jul 2023 to Jul 2024